

# Roberta Diaz Brinton

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1653387/roberta-diaz-brinton-publications-by-year.pdf>

**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

83 papers	6,682 citations	43 h-index	81 g-index
94 ext. papers	7,740 ext. citations	6.4 avg, IF	6.38 L-index

#	Paper	IF	Citations
83	Endogenous and Exogenous Estrogen Exposures: How Women's Reproductive Health Can Drive Brain Aging and Inform Alzheimer's Prevention.. <i>Frontiers in Aging Neuroscience</i> , <b>2022</b> , 14, 831807	5.3	1
82	Association of Reproductive History With Brain MRI Biomarkers of Dementia Risk in Midlife. <i>Neurology</i> , <b>2021</b> , 97, e2328-e2339	6.5	1
81	Menopause impacts human brain structure, connectivity, energy metabolism, and amyloid-beta deposition. <i>Scientific Reports</i> , <b>2021</b> , 11, 10867	4.9	11
80	Epigenetics of the developing and aging brain: Mechanisms that regulate onset and outcomes of brain reorganization. <i>Neuroscience and Biobehavioral Reviews</i> , <b>2021</b> , 125, 503-516	9	11
79	Mitochondria-Targeted Therapeutics for Alzheimer's Disease: The Good, the Bad, the Potential. <i>Antioxidants and Redox Signaling</i> , <b>2021</b> , 34, 611-630	8.4	6
78	Drug therapies for chronic conditions and risk of Alzheimer's disease and related dementias: A scoping review. <i>Alzheimer's and Dementia</i> , <b>2021</b> , 17, 41-48	1.2	5
77	Association between menopausal hormone therapy and risk of neurodegenerative diseases: Implications for precision hormone therapy. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , <b>2021</b> , 7, e12174	6	6
76	ApoE4 Impairs Neuron-Astrocyte Coupling of Fatty Acid Metabolism. <i>Cell Reports</i> , <b>2021</b> , 34, 108572	10.6	33
75	Preventing Alzheimer's disease within reach by 2025: Targeted-risk-AD-prevention (TRAP) strategy. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , <b>2021</b> , 7, e12190	6	1
74	Sex and APOE genotype differences related to statin use in the aging population. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , <b>2021</b> , 7, e12156	6	2
73	Allopregnanolone Promotes Neuronal and Oligodendrocyte Differentiation In Vitro and In Vivo: Therapeutic Implication for Alzheimer's Disease. <i>Neurotherapeutics</i> , <b>2020</b> , 17, 1813-1824	6.4	6
72	Transitions in metabolic and immune systems from pre-menopause to post-menopause: implications for age-associated neurodegenerative diseases. <i>F1000Research</i> , <b>2020</b> , 9,	3.6	12
71	Allopregnanolone Reverses Bioenergetic Deficits in Female Triple Transgenic Alzheimer's Mouse Model. <i>Neurotherapeutics</i> , <b>2020</b> , 17, 178-188	6.4	10
70	Statin therapy and risk of Alzheimer's and age-related neurodegenerative diseases. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , <b>2020</b> , 6, e12108	6	13
69	Sex-Related Differences in Brain Volumes and Cerebral Blood Flow Among Overweight and Obese Adults With Type 2 Diabetes: Exploratory Analyses From the Action for Health in Diabetes Brain Magnetic Resonance Imaging Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , <b>2020</b> , 75, 771-778	6.4	8
68	Association Between Hormone-Modulating Breast Cancer Therapies and Incidence of Neurodegenerative Outcomes for Women With Breast Cancer. <i>JAMA Network Open</i> , <b>2020</b> , 3, e201541	10.4	12
67	Autoimmune Disease in Women: Endocrine Transition and Risk Across the Lifespan. <i>Frontiers in Endocrinology</i> , <b>2019</b> , 10, 265	5.7	70

66	Effect of ApoE4 Genotype on the Association Between Metabolic Phenotype and Subclinical Atherosclerosis in Postmenopausal Women. <i>American Journal of Cardiology</i> , <b>2019</b> , 124, 1031-1037	3	0
65	Sex and Gender Driven Modifiers of Alzheimer's: The Role for Estrogenic Control Across Age, Race, Medical, and Lifestyle Risks. <i>Frontiers in Aging Neuroscience</i> , <b>2019</b> , 11, 315	5.3	37
64	Neuroendocrine aging precedes perimenopause and is regulated by DNA methylation. <i>Neurobiology of Aging</i> , <b>2019</b> , 74, 213-224	5.6	17
63	Data-driven identification of endophenotypes of Alzheimer's disease progression: implications for clinical trials and therapeutic interventions. <i>Alzheimer's Research and Therapy</i> , <b>2018</b> , 10, 4	9	20
62	F2-01-01: TRANSITIONS OF THE AGING FEMALE BRAIN: WINDOW INTO UNDERLYING MECHANISMS OF LATE ONSET ALZHEIMER'S DISEASE <b>2018</b> , 14, P601-P602		
61	Increased Alzheimer's risk during the menopause transition: A 3-year longitudinal brain imaging study. <i>PLoS ONE</i> , <b>2018</b> , 13, e0207885	3.7	59
60	Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , <b>2017</b> , 9, 10	9	104
59	Sex and Race Differences in the Association Between Statin Use and the Incidence of Alzheimer Disease. <i>JAMA Neurology</i> , <b>2017</b> , 74, 225-232	17.2	110
58	Perimenopause and emergence of an Alzheimer's bioenergetic phenotype in brain and periphery. <i>PLoS ONE</i> , <b>2017</b> , 12, e0185926	3.7	62
57	[F30401]: FUELING THE GLUCOSE-STARVED ALZHEIMER'S BRAIN: CATABOLISM OF WHITE MATTER IN THE BRAIN TO GENERATE KETONE BODIES <b>2017</b> , 13, P882-P883		1
56	Sex differences in Alzheimer risk: Brain imaging of endocrine vs chronologic aging. <i>Neurology</i> , <b>2017</b> , 89, 1382-1390	6.5	104
55	[P3025]: ALLOPREGNANOLONE, REGENERATIVE THERAPEUTIC FOR ALZHEIMER'S DISEASE: PHASE 1B/2A UPDATE <b>2017</b> , 13, P939-P940		3
54	Age, APOE and sex: Triad of risk of Alzheimer's disease. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , <b>2016</b> , 160, 134-47	5.1	266
53	Altered brain energetics induces mitochondrial fission arrest in Alzheimer's Disease. <i>Scientific Reports</i> , <b>2016</b> , 6, 18725	4.9	108
52	Identifying postmenopausal women at risk for cognitive decline within a healthy cohort using a panel of clinical metabolic indicators: potential for detecting an at-Alzheimer's risk metabolic phenotype. <i>Neurobiology of Aging</i> , <b>2016</b> , 40, 155-163	5.6	32
51	Neuroendocrinology: Oestrogen therapy affects brain structure but not function. <i>Nature Reviews Neurology</i> , <b>2016</b> , 12, 561-2	15	7
50	Postmenopausal hormone therapy, type 2 diabetes mellitus, and brain volumes. <i>Neurology</i> , <b>2015</b> , 85, 1131-8	6.5	20
49	Impact of Type 2 Diabetes and Postmenopausal Hormone Therapy on Incidence of Cognitive Impairment in Older Women. <i>Diabetes Care</i> , <b>2015</b> , 38, 2316-24	14.6	31

48	White Matter Lipids as a Ketogenic Fuel Supply in Aging Female Brain: Implications for Alzheimer's Disease. <i>EBioMedicine</i> , <b>2015</b> , 2, 1888-904	8.8	92
47	Allopregnanolone preclinical acute pharmacokinetic and pharmacodynamic studies to predict tolerability and efficacy for Alzheimer's disease. <i>PLoS ONE</i> , <b>2015</b> , 10, e0128313	3.7	28
46	Reversal of metabolic deficits by lipoic acid in a triple transgenic mouse model of Alzheimer's disease: a <sup>13</sup> C NMR study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>2014</b> , 34, 288-96	7.3	38
45	Hypermetabolic state in the 7-month-old triple transgenic mouse model of Alzheimer's disease and the effect of lipoic acid: a <sup>13</sup> C-NMR study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>2014</b> , 34, 1749-60	7.3	29
44	Frontiers in therapeutic development of allopregnanolone for Alzheimer's disease and other neurological disorders. <i>Frontiers in Cellular Neuroscience</i> , <b>2014</b> , 8, 203	6.1	47
43	Allopregnanolone as regenerative therapeutic for Alzheimer's disease: translational development and clinical promise. <i>Progress in Neurobiology</i> , <b>2014</b> , 113, 40-55	10.9	73
42	Estrogen: a master regulator of bioenergetic systems in the brain and body. <i>Frontiers in Neuroendocrinology</i> , <b>2014</b> , 35, 8-30	8.9	254
41	Potentiation of brain mitochondrial function by S-equol and R/S-equol estrogen receptor selective phytoSERM treatments. <i>Brain Research</i> , <b>2013</b> , 1514, 128-41	3.7	37
40	Early decline in glucose transport and metabolism precedes shift to ketogenic system in female aging and Alzheimer's mouse brain: implication for bioenergetic intervention. <i>PLoS ONE</i> , <b>2013</b> , 8, e79977	7.7	146
39	Ovariectomy induces a shift in fuel availability and metabolism in the hippocampus of the female transgenic model of familial Alzheimer's. <i>PLoS ONE</i> , <b>2013</b> , 8, e59825	3.7	52
38	Minireview: translational animal models of human menopause: challenges and emerging opportunities. <i>Endocrinology</i> , <b>2012</b> , 153, 3571-8	4.8	137
37	Ovarian hormone loss induces bioenergetic deficits and mitochondrial amyloid. <i>Neurobiology of Aging</i> , <b>2012</b> , 33, 1507-21	5.6	87
36	Allopregnanolone restores hippocampal-dependent learning and memory and neural progenitor survival in aging 3xTgAD and nonTg mice. <i>Neurobiology of Aging</i> , <b>2012</b> , 33, 1493-506	5.6	98
35	Estrogen regulation of mitochondrial bioenergetics: implications for prevention of Alzheimer's disease. <i>Advances in Pharmacology</i> , <b>2012</b> , 64, 327-71	5.7	60
34	Shift in brain metabolism in late onset Alzheimer's disease: implications for biomarkers and therapeutic interventions. <i>Molecular Aspects of Medicine</i> , <b>2011</b> , 32, 247-57	16.7	78
33	17β-Estradiol regulates insulin-degrading enzyme expression via an ERα/PI3-K pathway in hippocampus: relevance to Alzheimer's prevention. <i>Neurobiology of Aging</i> , <b>2011</b> , 32, 1949-63	5.6	97
32	2-Deoxy-D-glucose treatment induces ketogenesis, sustains mitochondrial function, and reduces pathology in female mouse model of Alzheimer's disease. <i>PLoS ONE</i> , <b>2011</b> , 6, e21788	3.7	114
31	Targeting mitochondrial bioenergetics for Alzheimer's prevention and treatment. <i>Current Pharmaceutical Design</i> , <b>2011</b> , 17, 3474-9	3.3	24

30	Estrogen protection against mitochondrial toxin-induced cell death in hippocampal neurons: antagonism by progesterone. <i>Brain Research</i> , <b>2011</b> , 1379, 2-10	3.7	32
29	Gonadal Hormones, Neurosteroids, and Clinical Progestins as Neurogenic Regenerative Agents: Therapeutic Implications <b>2011</b> , 281-303		
28	Allopregnanolone promotes regeneration and reduces amyloid burden in a preclinical model of Alzheimer's disease. <i>PLoS ONE</i> , <b>2011</b> , 6, e24293	3.7	89
27	Allopregnanolone reverses neurogenic and cognitive deficits in mouse model of Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2010</b> , 107, 6498-503	11.5	220
26	Decline in mitochondrial bioenergetics and shift to ketogenic profile in brain during reproductive senescence. <i>Biochimica Et Biophysica Acta - General Subjects</i> , <b>2010</b> , 1800, 1121-6	4	101
25	A select combination of clinically relevant phytoestrogens enhances estrogen receptor beta-binding selectivity and neuroprotective activities in vitro and in vivo. <i>Endocrinology</i> , <b>2009</b> , 150, 770-78	4.8	68
24	Estrogen-induced plasticity from cells to circuits: predictions for cognitive function. <i>Trends in Pharmacological Sciences</i> , <b>2009</b> , 30, 212-22	13.2	200
23	Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2009</b> , 106, 14670-5	11.5	639
22	Progesterone receptors: form and function in brain. <i>Frontiers in Neuroendocrinology</i> , <b>2008</b> , 29, 313-39	8.9	434
21	Allopregnanolone-induced rise in intracellular calcium in embryonic hippocampal neurons parallels their proliferative potential. <i>BMC Neuroscience</i> , <b>2008</b> , 9 Suppl 2, S11	3.2	32
20	Progesterone and estrogen regulate oxidative metabolism in brain mitochondria. <i>Endocrinology</i> , <b>2008</b> , 149, 3167-75	4.8	198
19	The healthy cell bias of estrogen action: mitochondrial bioenergetics and neurological implications. <i>Trends in Neurosciences</i> , <b>2008</b> , 31, 529-37	13.3	245
18	Estrogen regulation of glucose metabolism and mitochondrial function: therapeutic implications for prevention of Alzheimer's disease. <i>Advanced Drug Delivery Reviews</i> , <b>2008</b> , 60, 1504-11	18.5	107
17	Building a neuroscience legacy. <i>Journal of Neuroscience</i> , <b>2007</b> , 27, 11163-6	6.6	1
16	WHI and WHIMS follow-up and human studies of soy isoflavones on cognition. <i>Expert Review of Neurotherapeutics</i> , <b>2007</b> , 7, 1549-64	4.3	70
15	Estradiol in vivo regulation of brain mitochondrial proteome. <i>Journal of Neuroscience</i> , <b>2007</b> , 27, 14069-77	6.6	134
14	Therapeutic potential of neurogenesis for prevention and recovery from Alzheimer's disease: allopregnanolone as a proof of concept neurogenic agent. <i>Current Alzheimer Research</i> , <b>2006</b> , 3, 185-90	3	101
13	Preclinical analyses of the therapeutic potential of allopregnanolone to promote neurogenesis in vitro and in vivo in transgenic mouse model of Alzheimer's disease. <i>Current Alzheimer Research</i> , <b>2006</b> , 3, 11-7	3	44

12	Investigative models for determining hormone therapy-induced outcomes in brain: evidence in support of a healthy cell bias of estrogen action. <i>Annals of the New York Academy of Sciences</i> , <b>2005</b> , 1052, 57-74	6.5	126
11	Estrogen receptor $\beta$ as a therapeutic target for promoting neurogenesis and preventing neurodegeneration. <i>Drug Development Research</i> , <b>2005</b> , 66, 103-117	5.1	23
10	The neurosteroid allopregnanolone promotes proliferation of rodent and human neural progenitor cells and regulates cell-cycle gene and protein expression. <i>Journal of Neuroscience</i> , <b>2005</b> , 25, 4706-18	6.6	222
9	Estrogen receptor subtypes alpha and beta contribute to neuroprotection and increased Bcl-2 expression in primary hippocampal neurons. <i>Brain Research</i> , <b>2004</b> , 1010, 22-34	3.7	211
8	Requirements of a brain selective estrogen: advances and remaining challenges for developing a NeuroSERM. <i>Journal of Alzheimer's Disease</i> , <b>2004</b> , 6, S27-35	4.3	30
7	Mitochondria as therapeutic targets of estrogen action in the central nervous system. <i>CNS and Neurological Disorders</i> , <b>2004</b> , 3, 297-313		119
6	Mechanism of estrogen-mediated neuroprotection: regulation of mitochondrial calcium and Bcl-2 expression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2003</b> , 100, 2842-7	11.5	217
5	Selective estrogen receptor modulators (SERM) for the brain: Recent advances and remaining challenges for developing a NeuroSERM. <i>Drug Development Research</i> , <b>2002</b> , 56, 380-392	5.1	10
4	Neuroprotective and neurotrophic efficacy of phytoestrogens in cultured hippocampal neurons. <i>Experimental Biology and Medicine</i> , <b>2002</b> , 227, 509-19	3.7	126
3	The women's health initiative estrogen replacement therapy is neurotrophic and neuroprotective. <i>Neurobiology of Aging</i> , <b>2000</b> , 21, 475-96	5.6	90
2	Advances and challenges in the prevention and treatment of Alzheimer's disease. <i>Pharmaceutical Research</i> , <b>1998</b> , 15, 386-98	4.5	84
1	Vasopressin-induced neurotrophism in cultured hippocampal neurons via V1 receptor activation. <i>Journal of Neurobiology</i> , <b>1994</b> , 25, 380-94		25